AR046043A1 - Asociacion de un agente anti-aterotrombotico y un agente anti-agregacion de plaquetas y composiciones farmaceuticas que los contienen - Google Patents
Asociacion de un agente anti-aterotrombotico y un agente anti-agregacion de plaquetas y composiciones farmaceuticas que los contienenInfo
- Publication number
- AR046043A1 AR046043A1 ARP040103566A ARP040103566A AR046043A1 AR 046043 A1 AR046043 A1 AR 046043A1 AR P040103566 A ARP040103566 A AR P040103566A AR P040103566 A ARP040103566 A AR P040103566A AR 046043 A1 AR046043 A1 AR 046043A1
- Authority
- AR
- Argentina
- Prior art keywords
- agent
- association
- pharmaceutically acceptable
- aterotrombotic
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Asociación de un agente anti-aterotrombólico con un agente anti-agregación de plaquetas. Reivindicación 1: Asociación del compuesto (A) de fórmula (1), opcionalmente en forma de un isómero óptico, o de una de sus sales farmacéuticamente aceptables, y clopidogrel o una de sus sales farmacéuticamente aceptables. Reivindicación 5: Composición farmacéutica que comprende como ingredientes activos una asociación del compuesto (A), opcionalmente en forma de un isómero óptico, o una de sus sales farmacéuticamente aceptables, y clopidogrel o una de sus sales farmacéuticamente aceptables, en combinación con uno o más excipientes o vehículos inertes farmacéuticamente aceptables.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0311595A FR2860436B1 (fr) | 2003-10-03 | 2003-10-03 | Nouvelle association d'un anti-atherothrombotique et d'un antiagregant plaquettaire |
Publications (1)
Publication Number | Publication Date |
---|---|
AR046043A1 true AR046043A1 (es) | 2005-11-23 |
Family
ID=34307392
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040103566A AR046043A1 (es) | 2003-10-03 | 2004-10-01 | Asociacion de un agente anti-aterotrombotico y un agente anti-agregacion de plaquetas y composiciones farmaceuticas que los contienen |
Country Status (29)
Country | Link |
---|---|
US (2) | US20070054934A1 (es) |
EP (1) | EP1677779B1 (es) |
JP (1) | JP2007507475A (es) |
KR (1) | KR100782246B1 (es) |
CN (1) | CN100453075C (es) |
AR (1) | AR046043A1 (es) |
AT (1) | ATE409033T1 (es) |
AU (1) | AU2004277734B2 (es) |
BR (1) | BRPI0415043A (es) |
CA (1) | CA2540062A1 (es) |
CY (1) | CY1108388T1 (es) |
DE (1) | DE602004016762D1 (es) |
DK (1) | DK1677779T3 (es) |
EA (1) | EA009418B1 (es) |
ES (1) | ES2314457T3 (es) |
FR (1) | FR2860436B1 (es) |
GE (1) | GEP20084546B (es) |
HK (1) | HK1093900A1 (es) |
HR (1) | HRP20080546T3 (es) |
MA (1) | MA28081A1 (es) |
MX (1) | MXPA06003713A (es) |
MY (1) | MY137953A (es) |
NO (1) | NO20061944L (es) |
NZ (1) | NZ545988A (es) |
PL (1) | PL1677779T3 (es) |
PT (1) | PT1677779E (es) |
SI (1) | SI1677779T1 (es) |
UA (1) | UA80220C2 (es) |
WO (1) | WO2005032533A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA05014086A (es) * | 2005-12-20 | 2007-06-20 | Leopoldo De Jesus Espinosa Abdala | Composiciones farmaceuticas que comprenden sustancias antiagregantes plaquetarios combinadas para su uso en el tratamiento y prevencion de eventos vasculares de origen isquemico. |
FR2899473B1 (fr) * | 2006-04-07 | 2008-06-13 | Servier Lab | Utilisation d'un compose anti-atherothrombotique pour l'obtention de medicaments destines au traitement des troubles vasculaires |
EP2591783A1 (en) | 2007-04-13 | 2013-05-15 | Millennium Pharmaceuticals, Inc. | Combination anticoagulant therapy with a compound that acts as a factor Xa inhibitor |
FR2920772B1 (fr) * | 2007-09-11 | 2009-10-23 | Servier Lab | Association entre un anti-atherothrombotique et un inhibiteur de l'enzyme de conversion de l'angiotensine |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2711139B1 (fr) * | 1993-10-15 | 1995-12-01 | Adir | Nouveaux dérivés de 1,2,3,4-tétrahydronaphtalène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
US6509348B1 (en) * | 1998-11-03 | 2003-01-21 | Bristol-Myers Squibb Company | Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination |
-
2003
- 2003-10-03 FR FR0311595A patent/FR2860436B1/fr not_active Expired - Fee Related
-
2004
- 2004-01-10 UA UAA200604866A patent/UA80220C2/uk unknown
- 2004-10-01 EA EA200600657A patent/EA009418B1/ru not_active IP Right Cessation
- 2004-10-01 CN CNB2004800283560A patent/CN100453075C/zh not_active Expired - Fee Related
- 2004-10-01 WO PCT/FR2004/002489 patent/WO2005032533A1/fr active IP Right Grant
- 2004-10-01 BR BRPI0415043-0A patent/BRPI0415043A/pt not_active IP Right Cessation
- 2004-10-01 EP EP04791453A patent/EP1677779B1/fr active Active
- 2004-10-01 NZ NZ545988A patent/NZ545988A/en unknown
- 2004-10-01 MY MYPI20044026A patent/MY137953A/en unknown
- 2004-10-01 AR ARP040103566A patent/AR046043A1/es unknown
- 2004-10-01 GE GEAP20049368A patent/GEP20084546B/en unknown
- 2004-10-01 AT AT04791453T patent/ATE409033T1/de not_active IP Right Cessation
- 2004-10-01 KR KR1020067008071A patent/KR100782246B1/ko not_active IP Right Cessation
- 2004-10-01 ES ES04791453T patent/ES2314457T3/es active Active
- 2004-10-01 DK DK04791453T patent/DK1677779T3/da active
- 2004-10-01 AU AU2004277734A patent/AU2004277734B2/en not_active Ceased
- 2004-10-01 PT PT04791453T patent/PT1677779E/pt unknown
- 2004-10-01 PL PL04791453T patent/PL1677779T3/pl unknown
- 2004-10-01 CA CA002540062A patent/CA2540062A1/fr not_active Abandoned
- 2004-10-01 JP JP2006530412A patent/JP2007507475A/ja active Pending
- 2004-10-01 SI SI200430919T patent/SI1677779T1/sl unknown
- 2004-10-01 MX MXPA06003713A patent/MXPA06003713A/es active IP Right Grant
- 2004-10-01 US US10/574,119 patent/US20070054934A1/en not_active Abandoned
- 2004-10-01 DE DE602004016762T patent/DE602004016762D1/de active Active
-
2006
- 2006-04-03 MA MA28908A patent/MA28081A1/fr unknown
- 2006-05-02 NO NO20061944A patent/NO20061944L/no not_active Application Discontinuation
-
2007
- 2007-01-10 HK HK07100322.2A patent/HK1093900A1/xx unknown
-
2008
- 2008-09-30 CY CY20081101088T patent/CY1108388T1/el unknown
- 2008-12-03 HR HR20080546T patent/HRP20080546T3/xx unknown
-
2009
- 2009-11-09 US US12/590,489 patent/US20100056564A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR051405A1 (es) | Compuestos de 2-carboxamido(3-amino)tiofeno | |
ECSP055528A (es) | Composicion farmaceutica que tiene una distribución y potencia uniforme de farmaco | |
DOP2006000241A (es) | Composiciones farmacéuticas sólidas que contienen pregabalina | |
CL2008002687A1 (es) | Uso de una combinacion farmaceutica de un compuesto derivado de tieno[3,2-d]pirimidina con un agente quimioterapeutico en el tratamiento de un trastorno hiperproliferativo; kit farmaceutico. | |
AR088381A1 (es) | Formulaciones de etanercept estabilizadas con meglumina | |
UY29427A1 (es) | Derivados sustituidos de 2,3,4,5- tetrahidro-1h-pirido (4,3-b) indol, composiciones que los contienen, procesos de preparación y aplicaciones | |
AR024159A1 (es) | Nuevo uso de compuestos como agentes antibacterianos | |
ECSP066950A (es) | Combinaciones de glicopirrolato y agonistas del adrenoceptor-beta2 | |
MXPA06014470A (es) | Formulaciones oftalmicas que incluyen antagonistas de alfa 1 selectivas. | |
GT200900001A (es) | Composicion farmaceutica que contiene un acido tetra hidrofolico | |
NI200300042A (es) | Compuestos que modulan la actividad de ppar y metodos para su preparacion. | |
CR9081A (es) | Inhibidores de la interaccion entre mdm2 y p53 | |
PA8587101A1 (es) | Nuevos derivados de dihidropirimido [4,5-d] pirimidinona sustituida por amiino, fabricacion y uso de los mismos como agentes farmaceuticos | |
DOP2003000566A (es) | Cicloalcanindoles con sustitución con fluor, composiciones que contienen estos compuestos y metodos de preparación para un medicamento | |
AR039936A1 (es) | Formulacion farmaceutica de liberacion modificada | |
RS53209B (en) | PHARMACEUTICAL COMPOSITION FOR VIRAL HEPATITIS C PROTEASE INHIBITOR | |
GT200600200A (es) | Composicion farmaceutica que contienen gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato | |
PA8606201A1 (es) | DERIVADOS DE PIRROLO[3,4-c) PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA, PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN | |
DK1641803T3 (da) | Thienopyrimidinderivater som kaliumkanalinhibitorer | |
PE20211805A1 (es) | Formulaciones de un inhibidor de axl/mer | |
AR021578A1 (es) | Formulacion en perlas de pravastatina con revestimiento enterico | |
AR078283A1 (es) | Formulaciones de suspension oral de dibenzazepina carboxamidas | |
MX2022001161A (es) | Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmaceuticas que los contienen y sus usos como agentes proapoptoticos. | |
AR047279A1 (es) | Composicion detergente liquida | |
DE60142913D1 (de) | Arzneilösungen enthaltend modafinilverbindungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |